Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi Reports Successful Phase II Results For Obesity Treatment Velneperit; Analysts Lukewarm

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Osaka-based antibiotics manufacturer Shionogi reported positive results and "significant reduction in body weight" for its Phase II velneperit trial for obesity, but analysts were lukewarm about the results

You may also be interested in...



Shionogi Success As Global Player May Hinge on Obesity Drug In U.S., Analysts Say

TOKYO - In a bid to be recognized as a global player, mid-size pharmacuetical outfit Shionogi & Co. has been preparing to launch a few new drugs, including the anti-obesity drug S-2367 (velneperit), but analysts say it's too early to determine whether Shionogi can be successful overseas

Shionogi Success As Global Player May Hinge on Obesity Drug In U.S., Analysts Say

TOKYO - In a bid to be recognized as a global player, mid-size pharmacuetical outfit Shionogi & Co. has been preparing to launch a few new drugs, including the anti-obesity drug S-2367 (velneperit), but analysts say it's too early to determine whether Shionogi can be successful overseas

Shionogi Gains U.S. Sales Force With $1.4 Billion Sciele Acquisition

TOKYO - Shionogi moved Sept. 1 to establish a sales presence in the U.S. through the acquisition of Atlanta-based Sciele Pharma. Boards of both firms approved the $1.42 billion purchase, for $31 per share, prior to the announcement

Related Content

UsernamePublicRestriction

Register

SC070831

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel